Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Punit P Seth

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Molecular Therapy. Nucleic Acids|May 11, 2016
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and MonkeysColby S Shemesh, Rosie Z Yu, Hans J Gaus, et al.
Nucleic Acid Therapeutics|August 9, 2016
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in MonkeysRosie Z Yu, Rudy Gunawan, Noah Post, et al.
Nucleic Acids Research|February 5, 2021
Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOsGuillermo Vasquez, Graeme C Freestone, W Brad Wan, et al.
Nucleic Acids Research|April 30, 2019
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteinsMichael T Migawa, Wen Shen, W Brad Wan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 8, 2014
In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotidesAmber L Southwell, Niels H Skotte, Holly B Kordasiewicz, et al.
Plos One|September 11, 2014
Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patientsNiels H Skotte, Amber L Southwell, Michael E Østergaard, et al.
Nature Communications|August 11, 2015
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingKazutaka Nishina, Wenying Piao, Kie Yoshida-Tanaka, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Nucleic Acids Research|July 5, 2014
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in miceThazha P Prakash, Mark J Graham, Jinghua Yu, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Molecular Therapy. Nucleic Acids|May 11, 2016
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and MonkeysColby S Shemesh, Rosie Z Yu, Hans J Gaus, et al.
Nucleic Acid Therapeutics|August 9, 2016
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in MonkeysRosie Z Yu, Rudy Gunawan, Noah Post, et al.
Nucleic Acids Research|February 5, 2021
Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOsGuillermo Vasquez, Graeme C Freestone, W Brad Wan, et al.
Nucleic Acids Research|April 30, 2019
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteinsMichael T Migawa, Wen Shen, W Brad Wan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 8, 2014
In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotidesAmber L Southwell, Niels H Skotte, Holly B Kordasiewicz, et al.
Plos One|September 11, 2014
Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patientsNiels H Skotte, Amber L Southwell, Michael E Østergaard, et al.
Nature Communications|August 11, 2015
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingKazutaka Nishina, Wenying Piao, Kie Yoshida-Tanaka, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Nucleic Acids Research|July 5, 2014
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in miceThazha P Prakash, Mark J Graham, Jinghua Yu, et al.
Pageof 11